ClinicalTrials.gg

Program

RT-310

A development code. Also written as “RT-310 PK”.

Its studies are mostly in Prostatic Hyperplasia, led by Resurge Therapeutics.

Furthest: phase 2, since Nov 24, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Resurge Therapeutics33 open or runningphase 2since Nov 24, 2025Nov 9, 2023Dec 2028phase 2 · NCT07928206

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2023First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT06136819 · 20 enrolled · Australia, New Zealand
  2. Nov 24, 2025Phase 2 study in Prostatic HyperplasiaPhase 2 reachedNCT07264205 · 20 enrolled · Dominican Republic
  3. Oct 30, 2026Phase 2 study in Prostatic HyperplasiaNCT07928206 · 86 planned

Ahead

  1. Dec 2028Primary completion: phase 2 study in Prostatic HyperplasiaNCT07928206

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07928206Prostatic Hyperplasia2Not yet recruitingDec 202886
NCT07264205Prostatic Hyperplasia · Dominican Republic2Active, not recruitingFeb 26, 202620
NCT06136819Prostatic Hyperplasia · Australia, New Zealand1Active, not recruitingMay 6, 202520

How it is read

Names in the registry

  • “RT-310”, 3 entries
  • “RT-310 PK”, 1 entry

Codes read as this program: RT310.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.